Koç Healthcare, one of the leading health institutions in Türkiye, and the US -centered profit -based pre -profit -based organization Cross Cross, which is dedicated to making cell and gene therapies accessible, announced that it has signed a strategic cooperation that will increase access to gene therapies for patients in Türkiye. Within the scope of the cooperation, Chimmeric Antigen Receptor (CAR) is aimed to develop T-Hujre therapies and other advanced therapeutic pharmaceutical products (ATMPs) and to make life-saving treatments in Türkiye with a more appropriate budget for patients struggling with critical diseases.
It provides services as a unique expertise in the fields of research, development and production of CAR-T cells and other cellular gene therapies, including patented Car-T cell therapy developed for leukemia and lymphoma. This cooperation, developed with Koç Healthcare’s latest technology cellular therapy center in Türkiye, will eliminate logistics barriers and financial barriers and will access patients with timely -saving treatments.
CEO CEO Erhan Bulutcu, CEO of Aries, said: “As Koç Healthcare, we aim to provide the highest level of patient care by building a fully integrated ecosystem that brings together our accredited hospitals and advanced clinical research. Together with our Hospitals, Clinical Research Center (CTU), RMK Advanced Entrepreneurial Medicine, Education and Simulation Center (RMK AMES) and Translational Medicine Research Center (KUTTAM), we ensure that our patients benefit from the latest developments in medicine in many areas.
Pointing out the importance of the cooperation with Caring Cross, Bulutcu continued his words as follows: “We will create a sustainable domestic production model with Caring Cross and make the latest technology Car-T cell therapies accessible for numerous patients in Türkiye and to perform this at affordable costs. This initiative represents a great step in our mission of providing world -class health solutions. ”
